Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.
Miles Berger, MD, PhD
A Phase II Study of the ApoE mimetic peptide drug CN-105 to reduce Postoperative Delirium and Cognitive Dysfunction after Non-Cardiac Surgery in Older Adults and to Block their Underlying Mechanisms
A GuideStar-Rated Charity
© Copyright 2025. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).